Get the Stockscreener App
317.74
0.11%
0.36
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $317.74, with a volume of 2.19M.
It is up +0.11% in the last 24 hours and down -5.51% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$317.38
Open:
$317.3
24h Volume:
2.19M
Relative Volume:
0.83
Market Cap:
$171.10B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
24.56
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
-3.68%
1M Performance:
-5.51%
6M Performance:
+6.88%
1Y Performance:
+15.94%
1-Day Range:
$315.19
$319.46
1-Week Range:
$312.38
$329.67
52-Week Range:
$253.30
$346.38
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
317.74 | 170.90B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
BI Asset Management Fondsmaeglerselskab A S Has $23.15 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Bellevue Group AG Sells 56,827 Shares of Amgen Inc. $AMGN - MarketBeat
Banque Transatlantique SA Sells 141,712 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen’s Uplizna Approved For Its Largest And Most Competitive Indication Yet - Citeline News & Insights
FDA Grants Orphan Status to Amgen's (AMGN) Blinatumomab for Leuk - GuruFocus
Amgen (AMGN) Receives Maintained Rating, Price Target Lowered to - GuruFocus
FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease - Yahoo Finance
FDA Approves Amgen's Drug For Rare Muscle Disorder - Benzinga
Amgen (AMGN) Gains FDA Nod for Expanded Use of Uplizna in Myasth - GuruFocus
Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating - marketscreener.com
Amgen wins FDA nod for Uplizna in myasthenia gravis (AMGN) - Seeking Alpha
Quantinno Capital Management LP Purchases 19,014 Shares of Amgen Inc. $AMGN - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Peapack Gladstone Financial Corp Has $30.82 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Sei Investments Co. - MarketBeat
FDA approves Amgen’s UPLIZNA for generalized myasthenia gravis - Investing.com
FDA Approves Amgen's UPLIZNA for New Myasthenia Gravis Treatment - GuruFocus
FDA approves Amgen’s UPLIZNA for generalized myasthenia gravis By Investing.com - Investing.com Australia
Amgen (NASDAQ:AMGN) gets FDA OK for Uplizna as first CD19 B-cell therapy for gMG - Stock Titan
The Manufacturers Life Insurance Company Reduces Position in Amgen Inc. $AMGN - MarketBeat
NewEdge Advisors LLC Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer - GlobeNewswire Inc.
Wells Fargo Maintains Amgen (AMGN) Equal-Weight Recommendation - Nasdaq
Amgen Inc. (NASDAQ:AMGN) Announces Quarterly Dividend of $2.52 - MarketBeat
Amgen describes new GTPase KRAS mutant inhibitors - BioWorld MedTech
Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A "Buy" (NASDAQ:AMGN) - Seeking Alpha
Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Intact Investment Management Inc. Sells 10,800 Shares of Amgen Inc. $AMGN - MarketBeat
Ossiam Sells 13,818 Shares of Amgen Inc. $AMGN - MarketBeat
Wells Fargo Adjusts Price Target on Amgen to $325 From $300, Maintains Equalweight Rating - marketscreener.com
HSBC Adjusts Price Target on Amgen to $425 From $381, Maintains Buy Rating - marketscreener.com
Amgen (AMGN) to Participate in Upcoming Virtual Meeting - GuruFocus
Amgen Announces Dividend for the First Quarter of 2026, Payable on March 6, 2026 - marketscreener.com
Amgen Raises Quarterly Dividend to $2.52 a Share From $2.38, Payable March 6 to Shareholders of Record as of Feb. 13 - marketscreener.com
Amgen declares $2.52 per share dividend for first quarter 2026 By Investing.com - Investing.com UK
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND - PR Newswire
Key facts: Amgen invests $900M in Ohio; hosts Clinical Research Forum in UAE - TradingView
State Street Corp Increases Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by SVB Wealth LLC - MarketBeat
Who Owns Amgen? Top Shareholders and Recent Insider Trades - TIKR.com
Fayez Sarofim & Co Acquires 18,213 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Daiwa Securities Group Inc. - MarketBeat
Bank of Nova Scotia Has $29.83 Million Stake in Amgen Inc. $AMGN - MarketBeat
Axa S.A. Purchases 103,665 Shares of Amgen Inc. $AMGN - MarketBeat
Rep. David Taylor Sells Amgen Inc. (NASDAQ:AMGN) Stock - MarketBeat
Amgen Inc. $AMGN Shares Bought by L2 Asset Management LLC - MarketBeat
Gabelli Funds LLC Sells 3,150 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Boosted by Federated Hermes Inc. - MarketBeat
Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 68% Above Its Share Price - Yahoo Finance
Amgen Inc. $AMGN Shares Bought by Cerity Partners LLC - MarketBeat
Amgen Inc. $AMGN Shares Sold by California Public Employees Retirement System - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
2.28%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):